Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
Open Access
- 7 May 2020
- Vol. 69 (10), 1877-1884
- https://doi.org/10.1136/gutjnl-2019-319104
Abstract
Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.Keywords
This publication has 63 references indexed in Scilit:
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD programAlimentary Pharmacology & Therapeutics, 2012
- Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2012
- Prevalence and markers of advanced liver disease in type 2 diabetesQJM: An International Journal of Medicine, 2011
- Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factorsLiver International, 2011
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective StudyGastroenterology, 2011
- Relationship between Kidney Function and Liver Histology in Subjects with Nonalcoholic SteatohepatitisClinical Journal of the American Society of Nephrology, 2010
- Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver diseaseJournal of Hepatology, 2010
- Metabolic disturbances in non-alcoholic fatty liver diseaseClinical Science, 2009
- Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial designContemporary Clinical Trials, 2009
- Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic PatientsDiabetes Care, 2007